«We have demonstrated for the first time that Hsp90 inhibitors can block the production of the most common
abnormal androgen receptors that cause many prostate cancers to stop responding to current treatments.
Not exact matches
The new research found that on top of their known effects on cancer, Hsp90 inhibition also blocked production of
abnormal forms of the
androgen receptor, stripping cancer cells of their defences against hormone treatments.
However, cancer cells often generate
abnormal forms of the
androgen receptor that can be switched on all the time without the need for
androgen hormone stimulation.